Please use this identifier to cite or link to this item:
Title: Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Austin Authors: Spelman, Tim;Ozakbas, Serkan;Alroughani, Raed;Terzi, Murat;Hodgkinson, Suzanne;Laureys, Guy;Kalincik, Tomas;Van Der Walt, Anneke;Yamout, Bassem;Lechner-Scott, Jeannette;Soysal, Aysun;Kuhle, Jens;Sanchez-Menoyo, Jose Luis;Blanco Morgado, Yolanda;Spitaleri, Daniele LA;van Pesch, Vincent;Horakova, Dana;Ampapa, Radek;Patti, Francesco;Macdonell, Richard A L ;Al-Asmi, Abdullah;Gerlach, Oliver;Oh, Jiwon;Altintas, Ayse;Tundia, Namita;Wong, Schiffon L;Butzkueven, Helmut
Affiliation: MSBase Foundation, Melbourne, VIC, Australia.
Dokuz Eylul University, Izmir, Turkey.
Al-Amiri Hospital, Kuwait City, Kuwait.
Department of Neurology, 19 Mayis University, Samsun, Turkey.
Liverpool Hospital, Sydney, NSW, Australia.
University Hospital Ghent, Ghent, Belgium.
MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia/CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates/American University of Beirut Medical Center, Beirut, Lebanon.
School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia/Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia.
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
Multiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland/Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland.
Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain.
Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Ital.
Cliniques Universitaires Saint-Luc (UCLouvain), Brussels, Belgium.
Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
Nemocnice Jihlava, Jihlava, Czech Republic.
Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.
Neurology Unit, Department of Medicine, College of Medicine & Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University (SQU), Al Khodh, Oman.
Academic MS Center Zuyderland, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands/School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Division of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Koc University School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey.
EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
Issue Date: 2023
Date: 2022-11
Publication information: Multiple Sclerosis Journal 2023
Abstract: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience.
DOI: 10.1177/13524585221137502
ORCID: 0000-0001-9204-3216
Journal: Multiple Sclerosis Journal
Start page: 13524585221137502
PubMed URL: 36433775
ISSN: 1477-0970
Type: Journal Article
Subjects: MS
real-world data
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.